A comprehensive review of guidelines and consensus recommendations for managing women with multiple sclerosis during pre-pregnancy, pregnancy, and the postpartum phase - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A comprehensive review of guidelines and consensus recommendations for managing women with multiple sclerosis during pre-pregnancy, pregnancy, and the postpartum phase

  • By

  • Elaheh Mansouri Ghezelhesari

  • Malika Vaez Tehrani

  • Mohammadali Nahayati

  • Hosein Ebrahimipour

  • Abbas Heydari

  • Talat Khadivzadeh

  • February 14, 2026

Share

  • 1

    Multiple sclerosis (MS) predominantly affects women, with a prevalence ratio of 3:1 compared to men.

  • 2

    Women with MS face various complications that can impact their reproductive decisions and pregnancy intentions.

  • 3

    Despite the increasing number of women with MS of reproductive age, guidelines for managing their care during pregnancy remain incomplete.

  • 4

    The systematic review aims to compile and evaluate existing clinical recommendations for women with MS during pre-pregnancy, pregnancy, and postpartum.

  • 5

    The AGREE II tool was utilized to assess the quality of the guidelines included in the review, focusing on methodological rigor and clarity.

Original Source(s)

A comprehensive review of guidelines and consensus recommendations for managing women with multiple sclerosis during pre-pregnancy, pregnancy, and the postpartum phase

  • by Elaheh Mansouri Ghezelhesari, Malika Vaez Tehrani, Mohammadali Nahayati, Hosein Ebrahimipour, Abbas Heydari, Talat Khadivzadeh

  • February 14, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Cognitive Function and Fatigue in Stable Multiple Sclerosis: EDSS and MRI Assessments Surpass Serum Biomarkers

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.